Nivolumab: The New Second Line Treatment for Advanced Renal-cell Carcinoma Commentary on: Nivolumab Versus Everolimus in Advanced Renal-cell Carcinoma-Reference-Cited by-同舟云学术

Nivolumab: The New Second Line Treatment for Advanced Renal-cell Carcinoma Commentary on: Nivolumab Versus Everolimus in Advanced Renal-cell Carcinoma

Published:2016-03 Issue: Volume:89 Page:8-9
ISSN:0090-4295
Container-title:Urology
language:en
Short-container-title:Urology

Author:

Chedgy Edmund C.P.,Black Peter C.

Publisher

Elsevier BV

Subject

Urology

Reference6 articles.

1. Updated EAU guidelines for clear cell renal cancer patients who fail VEGF targeted therapy;Powles;Eur Urol,2015

2. Cabozantinib versus everolimus in advanced renal-cell carcinoma;Choueiri;N Engl J Med,2015

3. Sipuleucel-T immunotherapy for castration-resistant prostate cancer;Kantoff;N Engl J Med,2010

4. Sipuleucel-T (Provenge(R)) for castration-resistant prostate cancer;Di Lorenzo;BJU Int,2012

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. High-dimensional single-cell proteomics analysis of esophageal squamous cell carcinoma reveals dynamic alterations of the tumor immune microenvironment after neoadjuvant therapy;Journal for ImmunoTherapy of Cancer;2023-11

2. Early Changes of Serum Interleukin 14α Levels Predicts the Response to Anti-PD-1 Therapy in Cancer;Clinical Medicine Insights: Oncology;2023-01

3. Efficacy and Safety of Programmed Cell Death 1 Inhibitor Monotherapy Versus Chemotherapy as Second-Line Treatment for Advanced Esophageal Cancer: A Meta-analysis and Systematic Review;Clinical Therapeutics;2021-11

4. Choosing PD-1 Inhibitors in Oncology Setting, Left or Right?—Lessons From Value Assessment With ASCO-VF and ESMO-MCBS;Frontiers in Pharmacology;2020-12-18

5. PD-1 Inhibitors in the Advanced Esophageal Cancer;Frontiers in Pharmacology;2019-11-29